- Resource
- Source: Campus Sanofi
- 6 Oct 2025
Formulary & Service Support
This section has resources that you may require for your formulary submissions and business cases or policy reviews. As well as product information, therapy support resources and treatment guidelines. You can download these materials to better support your decision making.
CRSwNP
Dupixent® (dupilumab) Formulary Application Support Pack for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
This document provides factual and technical information about Dupixent to support relevant local formulary applications for CRSwNP.
Diabetes
Tzield®▼ (teplizumab) Value Proposition Leave Piece
Download this leave piece to understand the therapeutic value and potential cost benefits of TZIELD for payers and commissioners.
Tzield
Business Case Template
Information and guidance to support healthcare professionals and other relevant decision-makers to build a local business case for a TZIELD infusion delivery service.
Tzield Service Consideration Guide & Checklist
This document supports clinical teams and service commissioners in understanding the operational requirements, patient pathways, staffing needs and logistical considerations necessary to delivery the 14-day infusion treatment safely & effectively. Based on the:
- Product SmPC
- Expert advisory board feedback
- Real-world experience of TZIELD® delivery through a Managed Access Programme.
Tzield®▼ (teplizumab) Information Guide
This document provides factual and technical information about TZIELD to support your understanding of the product and relevant documentation for local formulary applications.
Tzield Birmingham Case Study
Case study from Birmingham, with practical, peer-to-peer insights and transferable learnings from a real-world implementation, covering how clinical, pharmacy, and nursing teams overcame operational challenges to deliver a 14-day infusion service within existing NHS infrastructure. Insights from the following healthcare professionals:
- Adults – Professor Parth Narendran
- Paediatrics – Renuka Dias
- Principal Pharmacist – Tayebah Abbasi
Respiratory
COPD - Eligible Population Estimator
This document provides information on estimating patients who might be eligable for Dupixent® (dupilumab) via the COPD indication.
COPD - Burden Analysis Model
Explore the impact that biologics could have on COPD services in regard to costs, admissions and stays within hospital.
Burden of COPD Infographic
An infographic showing the burden of COPD on hospital admissions, bed days and length of stay in England. For data relating to your ICB, please Get in Touch via the link below.
.jpg)
MAT-XU-2401933 (v5.0) Date of Preparation: May 2026